Javier Torralvo1, Alex Friedlaender1, Verane Achard2, Alfredo Addeo3. 1. Oncology Department, Geneva University Hospital, Geneva, Switzerland. 2. Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. 3. Oncology Department, Geneva University Hospital, Geneva, Switzerland alfredo.addeo@hcuge.ch.
Abstract
BACKGROUND/AIM: KRAS mutation is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). It is associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICIs), and data about their efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed the routine efficacy of ICIs in advanced KRAS-mutant NSCLC. PATIENTS AND METHODS: All stage IV NSCLC patients treated in our institution from January 2016 to December 2017 with immunotherapy were included in our analysis. We collected the status of KRAS and other mutations, as well as the type of ICI administered. We assessed four clinical outcomes: i) disease control rate (DCR), ii) partial response (PR), iii) progression-free survival (PFS) and iv) overall survival (OS). RESULTS: A total of 45 patients were initially identified but 7 were excluded due to insufficient clinical data, so 38 were included in the end. In the KRAS wild-type cohort, the DCR was 59% with 49% PR, while the PFS was 8.4 months and OS 16.8 months. Among KRAS mutated patients, results were more favourable, the DCR was 81%, with 62% PR. PFS was 13.6 months and OS was 18.5 months. The median follow-up was 24 months (17 to 34 months) and 7 patients were still on treatment at the time of analysis. CONCLUSION: Our data suggest that KRAS mutation is predictive of a superior response to immunotherapy. Furthermore, the lack of response of STK11 and KRAS co-mutated NSCLC patients to ICIs, is indeed negated by an additional TP53 mutation. Copyright
BACKGROUND/AIM: KRAS mutation is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). It is associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICIs), and data about their efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed the routine efficacy of ICIs in advanced KRAS-mutant NSCLC. PATIENTS AND METHODS: All stage IV NSCLCpatients treated in our institution from January 2016 to December 2017 with immunotherapy were included in our analysis. We collected the status of KRAS and other mutations, as well as the type of ICI administered. We assessed four clinical outcomes: i) disease control rate (DCR), ii) partial response (PR), iii) progression-free survival (PFS) and iv) overall survival (OS). RESULTS: A total of 45 patients were initially identified but 7 were excluded due to insufficient clinical data, so 38 were included in the end. In the KRAS wild-type cohort, the DCR was 59% with 49% PR, while the PFS was 8.4 months and OS 16.8 months. Among KRAS mutated patients, results were more favourable, the DCR was 81%, with 62% PR. PFS was 13.6 months and OS was 18.5 months. The median follow-up was 24 months (17 to 34 months) and 7 patients were still on treatment at the time of analysis. CONCLUSION: Our data suggest that KRAS mutation is predictive of a superior response to immunotherapy. Furthermore, the lack of response of STK11 and KRAS co-mutated NSCLCpatients to ICIs, is indeed negated by an additional TP53 mutation. Copyright
Authors: M Macerelli; C Caramella; L Faivre; B Besse; D Planchard; V Polo; M Ngo Camus; A Celebic; V Koubi-Pick; L Lacroix; J P Pignon; J C Soria Journal: Lung Cancer Date: 2014-01-03 Impact factor: 5.705
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Niki Karachaliou; Clara Mayo; Carlota Costa; Ignacio Magrí; Ana Gimenez-Capitan; Miguel Angel Molina-Vila; Rafael Rosell Journal: Clin Lung Cancer Date: 2012-11-01 Impact factor: 4.785
Authors: Shohei Koyama; Esra A Akbay; Yvonne Y Li; Amir R Aref; Ferdinandos Skoulidis; Grit S Herter-Sprie; Kevin A Buczkowski; Yan Liu; Mark M Awad; Warren L Denning; Lixia Diao; Jing Wang; Edwin R Parra-Cuentas; Ignacio I Wistuba; Margaret Soucheray; Tran Thai; Hajime Asahina; Shunsuke Kitajima; Abigail Altabef; Jillian D Cavanaugh; Kevin Rhee; Peng Gao; Haikuo Zhang; Peter E Fecci; Takeshi Shimamura; Matthew D Hellmann; John V Heymach; F Stephen Hodi; Gordon J Freeman; David A Barbie; Glenn Dranoff; Peter S Hammerman; Kwok-Kin Wong Journal: Cancer Res Date: 2016-02-01 Impact factor: 12.701
Authors: M B Schabath; E A Welsh; W J Fulp; L Chen; J K Teer; Z J Thompson; B E Engel; M Xie; A E Berglund; B C Creelan; S J Antonia; J E Gray; S A Eschrich; D-T Chen; W D Cress; E B Haura; A A Beg Journal: Oncogene Date: 2015-10-19 Impact factor: 9.867
Authors: J Mazieres; A Drilon; A Lusque; L Mhanna; A B Cortot; L Mezquita; A A Thai; C Mascaux; S Couraud; R Veillon; M Van den Heuvel; J Neal; N Peled; M Früh; T L Ng; V Gounant; S Popat; J Diebold; J Sabari; V W Zhu; S I Rothschild; P Bironzo; A Martinez-Marti; A Curioni-Fontecedro; R Rosell; M Lattuca-Truc; M Wiesweg; B Besse; B Solomon; F Barlesi; R D Schouten; H Wakelee; D R Camidge; G Zalcman; S Novello; S I Ou; J Milia; O Gautschi Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: G Saturno; F Lopes; I Niculescu-Duvaz; D Niculescu-Duvaz; A Zambon; L Davies; L Johnson; N Preece; R Lee; A Viros; D Holovanchuk; M Pedersen; R McLeary; P Lorigan; N Dhomen; C Fisher; U Banerji; E Dean; M G Krebs; M Gore; J Larkin; R Marais; C Springer Journal: Ann Oncol Date: 2020-10-29 Impact factor: 32.976
Authors: Nikolaj Frost; Jens Kollmeier; Claudia Vollbrecht; Christian Grah; Burkhard Matthes; Dennis Pultermann; Maximilian von Laffert; Heike Lüders; Elisabeth Olive; Matthias Raspe; Thomas Mairinger; Sebastian Ochsenreither; Torsten Blum; Michael Hummel; Norbert Suttorp; Martin Witzenrath; Christian Grohé Journal: Transl Lung Cancer Res Date: 2021-02